Gonadorelin
GnRH · LHRH · Factrel
FDA-APPROVED · GNRH DECAPEPTIDE (FDA-APPROVED)
▓ 171 indexed citations across PubMed (117), ClinicalTrials.gov (11), EuropePMC (43).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Background
Gonadorelin is a gonadotropin-releasing hormone agonist which is used in fertility medicine and to treat amenorrhea and hypogonadism. It is also used in veterinary medicine. The medication is a form of the endogenous GnRH and is identical to it in chemical structure. It is given by injection into a blood vessel or fat or as a nasal spray.
Mechanism of action
GnRH receptor agonist on pituitary; pulsatile stimulation of LH/FSH
Researched effects
LH/FSH stimulation; testosterone support; supports testicular function during exogenous testosterone use
Live evidence
Active clinical trials 5
- Trifecta Research Study
- Reprometabolic Syndrome Mediates Subfertility in Obesity
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
- Hormonal Mechanisms of Sleep Restriction - Axis Study
- GnRH Therapy on Cognition in Down Syndrome
Reported adverse events 528
Events spontaneously reported to the FDA FAERS database since 2015. A report does not establish that the drug caused the event, and counts do not reflect how often it occurs. Discuss any concern with a clinician.
FDA FAERS →Recent literature
- Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows.
- Diagnostic performance of a simplified GnRH stimulation test in central precocious puberty: a multicentre study
- Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols.
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
100 mcg SC 2x weekly (TRT adjunct starting dose, may go up to 300 mcg per dose 3x weekly per community protocols); 5 mcg IV pulses every 90 minutes (Lutrepulse pump for infertility)
→ FDA Lutrepulse prescribing information (pulsatile infertility dose); Crisler/Saya HRT protocol consensus for TRT adjunct (community standard)
Known concerns
Pituitary desensitization with continuous infusion
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?
- Hormonal cryptorchidism therapy: systematic review with metanalysis of randomized clinical trials.
- Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review.
- Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.
- Examining Differences in Pathological Outcomes and Safety for Prostate Cancer Patients Undergoing Either Subcapsular Orchiectomy or Medical Androgen Deprivation Therapy: A Systematic Review.
- Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.
- The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.
- Treatment of Paraphilic Disorders in Sexual Offenders or Men With a Risk of Sexual Offending With Luteinizing Hormone-Releasing Hormone Agonists: An Updated Systematic Review.
- Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review.
- Effect of 200 µg of gonadorelin at the first gonadotropin-releasing hormone of the Resynch-25 on ovarian dynamics and fertility in lactating Holstein cows.
Full citation library
Year distribution
No references match — clear filters.
Meta-Analyses
2-
1.
Treatment of triple-negative breast cancer (TNBC) imposes great challenges, due to a lack of molecular targets. While use of gonadotropin-releasing hormone (GnRH) analogs has been validated in ER-positive breast cancer, this option has not been investigated in TNBC, even though a significant portion of these tumors upregulate GnRH receptors. We performed a meta-analysis of the literature to evaluate the effect of GnRH analogs in TNBC. Four studies were included in this study. We detected a non-s…
-
2.
The importance of cryptorchidism treatment concerns the possibility of diminishing risk of malignant degeneration and improving fertility. Success rates of hormonal treatment vary: 0-55% with human chorionic gonadotropin (hCG) and 9-78% with gonadotropin-releasing hormone (GnRH). Due to uncertainties regarding the effectiveness of this treatment, a systematic review and meta-analysis of randomized controlled trials (RCTs) on hormonal cryptorchidism treatment was done using the methodology of Coc…
Systematic Reviews
7-
3.
The hypothalamus-pituitary-gonadal (HPG) axis is the endocrine regulation system that controls the woman's cycle. The gonadotropin-releasing hormone (GnRH) plays the central role. In addition to the gonadotrophic cells of the pituitary, GnRH receptors are expressed in other reproductive organs, such as the ovary and in tumors originating from the ovary. In ovarian cancer, GnRH is involved in the regulation of proliferation and metastasis. The effects on ovarian tumors can be indirect or direct.…
-
4.
Endometrial cancer (EC) is one of the most common gynecological malignancies. Gonadotropin releasing hormone (GnRH) is a decapeptide first described to be secreted by the hypothalamus to regulate pituitary gonadotropin secretion. In this systematic review, we analyze and summarize the data indicating that most EC express GnRH and its receptor (GnRH-R) as part of an autocrine system regulating proliferation, the cell cycle, and apoptosis. We analyze the available data on the expression and functi…
-
5.
In addition to psychotherapy, pharmacotherapy is an important treatment option for paraphilias, especially in sexual offenders. Cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) are commonly used but can have serious side effects. Selective serotonin reuptake inhibitors (SSRIs) may also be effective in less severe cases. Recent research shows that luteinizing hormone-releasing hormone (LHRH) agonists may offer a new treatment option for treatment of paraphilic patients. MEDLINE was…
-
6.
Different pharmacologic agents are used in the treatment of paraphilic disorders in sexual offenders or men with a risk of sexual offending, with luteinizing hormone-releasing hormone (LHRH) agonists being the agents introduced more recently to treatment regimens. To summarize the relevant literature concerning LHRH agonist treatment of paraphilic disorders in sexual offenders and update the previously published systematic review by Briken et al (J Clin Psychiatry 2003;64:890-897). The PubMed an…
-
7.
<b>Background:</b> G-protein-coupled receptors (GPCRs) play pivotal roles in tumor growth and progression. Among these, the luteinizing hormone-releasing hormone receptor (LHRH-R) and follicle-stimulating hormone receptor (FSH-R) represent promising translational targets, unlike luteinizing hormone receptors (LH-Rs). Indeed, both LHRH-R and FSH-R are selectively expressed in various cancers and their vasculature, offering opportunities for receptor-mediated imaging and therapy. <b>Objectives:</b…
-
8.
<h4>Purpose</h4>The purpose of this systematic review is to investigate differences in pathological outcomes and safety between subcapsular orchiectomy and pharmacological androgen deprivation therapy (ADT) for prostate cancer management.<h4>Methods</h4>A systematic search was conducted on PubMed, Google Scholar, and ScienceDirect for original articles published until February 2024 that compared tumour characteristics, biochemical markers, and adverse effects associated with these treatments. Th…
-
9.
<h4>Objective</h4>The escalating incidence of prostate cancer poses a significant global public health challenge. Optimal utilization of resources is crucial for the effective deployment of funds among the diverse and emerging treatment options for managing prostate cancer. This systematic review aims to offer insights and serve as a reference for pharmacoeconomic studies related to the use of degarelix and luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of prostate cancer…
Randomised Controlled Trials
8-
10.
The standard treatment for boys with non-syndromic cryptorchidism is an early orchidopexy. It is unclear if surgical intervention alone is enough for future fertility. Recent studies show benefit of neoadjuvant or adjuvant hormonal treatment with gonadorelin (GnRH) for spermatogonia maturation based on testicular biopsy. The aim of this prospective study was to assess the safety of this treatment in infants with undescended testis at the recommended timing of early gonadorelin administration and…
-
11.
Difference in breed, nutrition status and climate in which animals are managed result in differences in response to reproductive hormones. Fertility rate to artificial insemination is very low in Ethiopian Boran and Boran*Holstein crosses. This partly maybe due to adopting estrus and/or ovulation synchronization developed for temperate taurine cattle. Experimental study was conducted to evaluate ovarian response to combinations of Gonadotrophin-Realizing Hormone agonist (gonadorelin) and Prostag…
-
12.
This study aimed to determine the effect of circulating progesterone (P4) concentrations produced by a corpus luteum (CL) or released by an intravaginal P4 implant (IPI) on GnRH-induced LH release, ovulatory response, and subsequent CL development, after treatment with 100 μg of gonadorelin acetate (GnRH challenge). Nonlactating multiparous Holstein cows were synchronized and GnRH was used to induce ovulation (d -7). Over 4 replicates, cows that ovulated (n = 87) were randomly assigned to a 2 ×…
-
13.
The objective of the present study was to evaluate the effect of GnRH dose administered at initiation (GnRH-1) of a 5-day CO-Synch + P4 protocol on ovulatory response, expression of estrus, and fertility in suckled beef cows. Suckled beef cows (n = 1101) at four locations were randomized to receive either 100 or 200 µg of gonadorelin acetate at initiation (D-8) of a 5-day CO-Synch + P4 protocol concurrently with insertion of an intravaginal progesterone (P4) device. On D-3 the P4 device was remo…
-
14.
Our objective was to determine the effect of a 200-µg dose of GnRH 25 d after previous artificial insemination (AI) in a Resynch-25 resynchronization program on ovulatory response, circulating progesterone (P4) concentrations before and after treatment, and pregnancy per AI (P/AI) compared with a 100-µg dose in lactating Holstein cows. Experimental d 0 was considered the day of the previous AI. Lactating dairy cows (n = 3,240) with an average of 126 d in milk (DIM) and between 1 and 6 services w…
-
15.
The objectives of the current experiment were to determine if delaying insemination by 8 h in a FTAI protocol would alter estrus expression and pregnancy rates in cows inseminated with sex-sorted semen, characterize bull variation in pregnancy rates to sex-sorted semen and examine the impact of repeated years of FTAI to sex-sorted semen on calving distribution. Over three breeding seasons, postpartum cows (n = 839) were estrous synchronized using the 5-day CO-Synch + CIDR system. Cows were given…
-
16.
The objectives of this study were to determine the effects of GnRH at the time of artificial insemination (AI) on ovulation, progesterone 7 d post-AI, and pregnancy in cows detected in estrus using traditional methods (tail chalk removal and mount acceptance visualization) or an automated activity-monitoring (AAM) system. We hypothesized that administration of GnRH at the time of AI would increase ovulation rate, plasma progesterone post-AI, and pregnancy per AI (P/AI) in cows detected in estrus…
-
17.
Timed artificial insemination (TAI) is an efficient reproductive technology in batch farrowing production that aids management in pig farms. However, the effect of TAI on the reproduction performance is still controversial. This study aimed to evaluate the effects of two TAI protocols on the reproductive performance of primiparous sows. A total of 332 weaned sows were randomly allocated into three treatments. Sows assigned to Control (n = 110) were untreated and inseminated on each day in oestru…
Clinical Trials
5-
18.
Different GnRH products are used for timed artificial insemination (AI) in postpartum dairy cows. Previous studies reported greater LH release and increased ovulation percentage for gonadorelin diacetate tetrahydrate compared with gonadorelin hydrochloride but pregnancies per AI (P/AI) were not evaluated. The objective, therefore, was to compare P/AI for cows treated with either gonadorelin hydrochloride or gonadorelin diacetate tetrahydrate before the first timed AI or resynchronized timed AI.…
-
19.
This study was designed to evaluate the potential of using eCG or GnRH in restoring reproductive functions in GnRH immunized ewes. Thirty-three multiparous Kivircik ewes were randomly assigned into either control group (n=11) or immunization group (n=22). Ewes were immunized against GnRH by injecting with a cocktail of ovalbumin-LHRH-7 (ovalbumin-GnRH-7) and thioredoxin-LHRH-7 (thioredoxin-GnRH-7) fusion proteins generated by recombinant DNA technology in April. 500 IU eCG or 0.008 mg GnRH analo…
-
20.
Plasma luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, estradiol (E2) and progesterone were measured in 24 normal, adult women before and after i.v. administration of 100 micrograms luteinizing hormone releasing hormone (LHRH; Factrel) and p.o. ingestion of an alcohol (0.694 g of alcohol per kg b.wt.) or placebo solution. Twelve subjects were studied during the early follicular phase of the menstrual cycle and 12 subjects were studied during the midluteal phase of the me…
-
21.
Human menopausal gonadotropin has been the treatment of choice for hypogonadotropic hypogonadism patients who fail ovulation induction with clomiphene citrate. Several authors have reported successful ovulation induction with the use of gonadotropin releasing hormone (GnRH). We used commercially available GnRH (Factrel, Ayerst Laboratories) and the Auto Syringe AS6H Infusion Pump for ovulation induction in such patients. Eight patients completed 15 cycles of pulsatile intravenous GnRH therapy. A…
-
22.
Gonadotrophin releasing hormone (GnRH) is commonly used in llamas to induce ovulation; however, the consequence of reduced doses of GnRH on luteinizing hormone (LH) release, ovulatory response, and subsequent corpus luteum (CL) development and function have apparently not been investigated. Hence, we examined the effect of gradual reduction of gonadorelin acetate (GnRH) dosage on pituitary LH release, ovulatory response, CL development, and plasma progesterone concentrations in llamas. Non-pregn…
Trial Registrations (ClinicalTrials.gov)
11-
23.
Conditions: Pregnancy, Embryo Implantation
-
24.
Conditions: Hypogonadism
-
25.
Conditions: Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer
-
26.
Conditions: Prostate Cancer With ≤10 Bone Metastases
-
27.
Conditions: Prostate Cancer
- 28.
-
29.
Conditions: Prostatic Neoplasms
-
30.
Conditions: Prostate Cancer
- 31.
-
32.
Conditions: PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury (+2)
-
33.
Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 (+4)
Reviews
26-
34.
Gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) hypothalamic hormone that acts upon 7-trans membrane spanning GnRH receptors in the pituitary. This action leads to the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that in turn act on the reproductive organs regulating gonadal steroid production, spermatogenesis and follicular development. Peptidi…
-
35.
Gonadotropin-releasing-hormone (GnRH) analogues are synthetic compounds derived from decapeptide neurohormones (LHRH; LH/FSH-RH). They have a key role in hormone dependent cancer, particularly breast and prostate cancer. GnRH analogues produce an efficient inhibition of gonadotropins and sex steroid hormones. Their use in cancer therapy result in a, pharmacological castration (i.e. ovariectomy and orchiectomy), providing an androgen and estrogen ablation. GnRH exert an inhibitory action on the g…
-
36.
The expression of GnRH (GnRH-I, LHRH) and its receptor as a part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors, including cancers of the ovary. The proliferation of human ovarian cancer cell lines is time- and dose-dependently reduced by GnRH and its superagonistic analogs. The classical GnRH receptor signal-transduction mechanisms, known to operate in the pituitary, are not involved in the mediation of antiproliferative effec…
-
37.
The gonadotrophin-releasing hormone (GnRH) antagonist binds competitively to the receptors and thereby prevents endogenous GnRH from exerting its stimulatory effect on the pituitary cells. This causes suppression of gonadotrophin secretion which occurs immediately after administration of the antagonist. When using GnRH antagonist in controlled ovarian stimulation, ovulation or maturation of the oocyte can, therefore, be induced by a variety of drugs, e.g. native GnRH, recombinant LH or short-act…
-
38.
Gonadotropin-releasing hormone (GnRH, previously called leutinizing hormone-releasing hormone, LHRH) is the final common signaling molecule used by the brain to regulate reproduction in all vertebrates. Recently, genes encoding two other GnRH forms have been discovered. Here we present a phylogenetic analysis that shows that the GnRH genes fall naturally into three distinct branches, each of which shares not only a molecular signature but also characteristic expression sites in the brain. The Gn…
-
39.
The neuropeptide gonadotropin-releasing hormone (GnRH, LHRH) serves as both a hormone and a neurotransmitter, and it has multiple actions on reproductive physiology and behavior. At least seven different molecular forms of GnRH have evolved, and nearly all vertebrates studied express at least two different forms of GnRH: chicken GnRH II, and a second form that varies across classes. The GnRH cell bodies span a broad region of the forebrain and midbrain, and processes project to virtually every r…
-
40.
Ovarian cancer remains one of the most lethal gynecologic malignancies and requires more effective and targeted treatment strategies. Luteinizing hormone-releasing hormone (LHRH), or gonadotropin-releasing hormone (GnRH), receptors are expressed in approximately 80% of ovarian tumors, representing a promising target for targeted drug delivery. This narrative review aimed to explore the development and advancements of LHRH-receptor targeted therapies in ovarian cancer. A bibliographic search was…
-
41.
In the present study, the possible direct effects of opioids on the release of LHRH have been studied utilizing the GT1-1 cell model. It has been shown that only opioid agonists which bind to delta receptors bring about a significant inhibition of the release of LHRH, when this is stimulated by forskolin- or PGE2. The effects of delta opioid agonists are dose-dependent, and are reversed by the delta specific antagonist naltrindole. If one assumes that the GT1-1 cells represent a good model for t…
-
42.
The fundamental aspects of the hypothalamic luteinizing hormone-releasing hormone (LHRH)(1) [1]pulse generator-pituitary gonadotrophin-gonadal apparatus in mammals have striking commonalities. There are, however, critical, substantive differences in the neuroendocrinology of puberty among species. The onset of puberty in the human is marked by an increase in the amplitude of LH pulses, an indirect indicator of the increase in amplitude of LHRH pulses. The hypothalamic LHRH-pituitary gonadotrophi…
-
43.
Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic p…
-
44.
Major advances in our understanding of the synthesis and release of anterior pituitary hormones have been made over the past several years. Neurons of the hypothalamus have been found to serve as "neuroendocrine transducers" in that they have both electrical and secretory functions. Peptidergic neurons respond to appropriate stimuli with a release of hypothalamic factors into the hypophyseal-portal system. These factors or hormones ultimately control the endocrine function of anterior pituitary…
-
45.
GnRH agonists have a proven and well-established role in the management of prostate cancer. Further adaptations of the amino-acid sequence led to the development of antagonists with potential therapeutic uses, including a possible role in prostate cancer patients. Treatment of prostate cancer with GnRH agonists results in an initial flare of symptoms that may be prevented by co-administration of a steroidal or non-steroidal antiandrogen. However, this can be associated with additional adverse ef…
-
46.
The main systemic therapy for the management of hormone-sensitive prostate cancer (PC) is androgen deprivation therapy (ADT), with the use of long-acting luteinizing hormone releasing-hormone (LHRH) agonists considered the main form of ADT used in clinical practice to obtain castration in PC. The concomitant administration of antiandrogens for the first weeks could reduce the incidence of clinical effects related to the testosterone flare-up in the first injection of LHRH. On the contrary, Gonad…
-
47.
Endometriosis is an extremely common gynaecological disease, affecting between 1 and 5% of women of reproductive age. Women with endometriosis typically present for medical care with one of more of the following problems: pelvic pain, infertility, or a large adnexal mass (an endometrioma). The primary treatment for an endometrioma is surgical. However, long term postoperative hormone therapy may be necessary to prevent new endometriomas from developing. There is no evidence that hormonal therapy…
-
48.
Androgen deprivation therapy (ADT) has been the standard of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for 3 decades. The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT. The application of agonists of LHRH has improved and modernized the treatment of advanced PCa; millions of patients have benefited from therapy with LHRH agonists as a preferred alte…
-
49.
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists is the mainstay of treatment for metastatic prostate cancer (mCaP). However, ADT is associated with serious cardiovascular events. Only a few studies that directly compare the cardiovascular risk of LHRH agonists versus GnRH antagonists have been published. This review aims to compare the cardiovascular risk of LHRH agonists versus GnRH antagonists based on the literature. A literature sear…
-
50.
Preovulatory surges of luteinizing hormone (LH) depend upon neurotransmitter activation of neurons that secrete LH-releasing hormone (LHRH, gonadotropin-releasing hormone GnRH) and noradrenaline plays a pivotal role in this critical event. The interaction is amongst noradrenaline and other neurotransmitters such as GABA (gamma-aminobutyric acid), opiates, serotonin and excitatory amino acids (N-methyl-D-aspartate, NMDA) on LHRH neuronal activity are complex. GABA and opiates suppress the presyna…
-
51.
Hormonal therapy is the main recommended treatment for locally advanced and metastatic prostate cancer. Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels. However, this reduction is accompanied by a well described increase or 'surge' in LH and testosterone levels…
-
52.
Neuropeptide processing metalloenzymes, such as angiotensin converting enzyme, neprilysin, endothelin converting enzyme, neurolysin, and EC3.4.24.15 (EP24.15), are central to the formation and degradation of bioactive peptides. We present EP24.15 as a paradigm for novel functions ascribed to these enzymes in the neurome. Although the neurome typically encompasses proteomes of the brain and central nervous system, exciting new roles of these neuropeptidases have been demonstrated in other organ s…
-
53.
Fractionation of hypothalamic extracts on a Sephadex G-25 column separates follicle-stimulating hormone-releasing factor (FSHRF) from luteinizing hormone-releasing hormone (LHRH). The FSH-releasing peak contained immunoreactive lamprey gonadotropin-releasing hormone (lGnRH) by radioimmunoassay, and its activity was inactivated by an antiserum specific to lGnRH. The identity of lGnRH-III with FSHRF is supported by studies with over 40 GnRH analogs that revealed that this is the sole analog with p…
-
54.
The objective of this study was provide an overview of current practices on hormonal therapy (HT) in children with undescended testes (UDT). An online questionnaire about HT, referral patterns, and orchidopexy was spread via several (social media) networks involved in pediatric urology. A total of 283 individuals responded, with 54 countries sampled. The majority (84%) did not prescribe HT for UDT, predominantly due to a paucity of scientific evidence (76%). Among those who use HT, main reason w…
-
55.
In the 60 years since Huggins first demonstrated the hormone dependency of prostate cancer, the introduction of various means of hormonal manipulation has resulted in modest achievements. Orchiectomy reduced testosterone but was irreversible and associated with reduced quality of life. Diethylstilbestrol (DES) represented the first alternative to surgical castration. However, cardiovascular adverse events severely limited its use. The luteinizing hormone-releasing hormone (LHRH) agonists offered…
-
56.
While hormonal therapy has been the usual and appropriate treatment of advanced or metastatic prostatic cancer for the past 50 years, the recent development of new therapeutic agents as medical alternatives to orchidectomy has drastically altered the options and perspectives in the treatment of this disease. Estrogens had been the only commonly used drug therapy in the United States. Newer alternatives include androgen synthesis inhibitors, a class of agents termed antiandrogens, and gonadotroph…
-
57.
Prostate cancer sometimes metastasizes, especially to bone, which may cause pain, fractures and spinal cord compression. What are the best first-line treatment options for patients with metastatic prostate cancer? To answer this question, we conducted a review of the literature, using the standard Prescrire methodology. Suppressing androgen secretion by surgically removing the testicles (orchiectomy) or by administering a gonadorelin agonist relieves the pain associated with bone metastases in a…
-
58.
Prostate cancer is a growing health problem with considerable economic consequences. Despite progress in the management of this disease, few areas in medicine generate greater disagreement. The larger part of healthcare resources are allocated to 'halfway technologies' aimed at palliative intervention to prolong life, while a relatively small part goes to measures aimed at preventing or curing the disease. The aetiology of this cancer is multifactorial and no practical measures for primary preve…
-
59.
LHRH (GNRH) was first isolated in the mammalian hypothalamus and shown to be the primary regulator of the reproductive neuroendocrine axis comprising of the hypothalamus, pituitary and gonads. LHRH acts centrally through its initiation of pituitary gonadotrophin release. Since its discovery, this form of LHRH (LHRH-I) has been shown to be one of over 20 structural variants with a variety of roles in both the brain and peripheral tissues. LHRH-I is processed by a zinc metalloendopeptidase EC 3.4.…
Research Articles
107-
60.
In vertebrates, folliculogenesis and ovulation are regulated by two distinct pituitary gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Currently, there is an intriguing consensus that a single hypothalamic neurohormone, gonadotropin-releasing hormone (GnRH), regulates the secretion of both FSH and LH, although the required timing and functions of FSH and LH are different. However, recent studies in many non-mammalian vertebrates indicated that GnRH is dispensable…
-
61.
This study evaluated whether the four gonadorelin products that are commercially available in the United States produce comparable ovulation responses in lactating cows. Dairy cows at 7 d after last gonadotropin-releasing hormone (GnRH) treatment of Ovsynch (Day 7), with a corpus luteum (CL) > or =15 mm and at least one follicle > or =10mm, were evaluated for response to GnRH treatment. Selected cows were randomized to receive (100 microg; im): (1) Cystorelin (n=146); (2) Factrel (n=132); (3) Fe…
-
62.
A nadir of LH precedes the onset of the flush and a flush is never seen without an LH pulse. However, after surgical and medical (GnRH agonist) hypophysectomy flushing occurs while LH is absent, thus LH itself is not the cause of the flush. GnRH agonist treatment induces low LH, whereas flushes remain, even when oestrogens are supplemented, suggesting that GnRH itself is the mediator. As flushes are preceded by a spike of LH-RH, GnRH involvement is most likely. Pulsatile administration of GnRH d…
-
63.
The reproductive performance of goats that received a GnRH analog (gonadorelin) fabricated with or without chitosan-sodium tripolyphosphate (TPP) nanoparticles on the day of estrus (day 0) was evaluated. The chitosan-TPP polymer was conjugated with gonadorelin using an ionic gelation method. Thirty-three multiparous Zaraiebi goats were synchronized for estrus with 2 intramuscular (im) injections of 125 μg prostaglandin F
-
64.
The objective was to determine luteinizing hormone (LH) secretion and follicular dynamics in cattle following administration of 3 gonadorelin formulations that are commercially available in Canada. In experiment 1, nonlactating Holstein cows (n = 4 per group) were randomly assigned to receive 100 micrograms gonadorelin diacetate tetrahydrate, intramuscularly (C; Cystorelin, or FE; Fertagyl). Blood samples (for LH analysis) were collected 0, 1, 2, and 4 hours after treatment. In experiment 2, non…
-
65.
This study was designed to evaluate whether commonly used gonadorelin products that are commercially available in the United States results in comparable ovulation and pregnancy per AI (P/AI) in synchronized lactating dairy cows. A total of 1411 Holstein cows receiving a Double-Ovsynch protocol (DOV) for conducting the first postpartum AI were randomized to receive one of the following GnRH products throughout the Double-Ovsynch: 1) Cystorelin® (CYS, gonadorelin diacetate tetrahydrate, n = 484);…
-
66.
The gonadotropin-releasing hormone (GnRH) stimulation test is used to investigate testicular production of testosterone (T) when performing a breeding soundness examination. In male dogs with fertility problems, the prostate should also be investigated as prostatic conditions may frequently lower semen quality. Serum concentrations of canine prostatic-specific esterase (CPSE) increase in dogs with benign prostatic hyperplasia (BPH). When performing a breeding soundness examination in a male dog,…
-
67.
In Expt 1, gonadotropin-releasing hormone (GnRH) (Cystorelin, CEVA) was administered intramuscularly to two intact male dogs; one dog received one injection of 50 micrograms GnRH and one dog received four daily injections of 50 micrograms GnRH. Both dogs exhibited a significant and immediate rise in luteinizing hormone (LH) following GnRH administration, with a peak observed at 15 min following injection. Testosterone was increased over baseline concentrations for 5 and 7 days, respectively, aft…
-
68.
Detection of gonadotropin-releasing hormone (GnRH) also known as luteinizing hormone-releasing hormone (LHRH) in the relevant tumor tissue and normal tissues and organs
-
69.
The initial ovulatory response during synchronization programs is often low in dairy heifers, largely due to follicular dynamics and hormonal dynamics. Specifically, the progesterone (P4) concentration at the time of the first GnRH treatment in a breeding program can influence the LH response, often resulting in a suboptimal ovulatory response. The objective of this study was to determine the effect of the highest label dose 200 μg (100 μg vs. 200 μg) of GnRH (50 μg of gonadorelin hydrochloride…
-
70.
Gonadotropin-releasing hormone (GnRH), a decapeptide synthesized and released by the hypothalamus, regulates production and release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the adenohypophysis. Parenterally administered GnRH was initially used diagnostically as a test of adenohypophyseal reserve of LH and FSH. Subsequently, native GnRH was used therapeutically to treat hypothalamic hypogonadal and infertility states in both men and women. Because of…
-
71.
Analogs of gonadoliberin (GnRH) are widely used in cattle to synchronize estrus and to induce ovulation, as well as for the treatment of ovarian cysts. The aim of this study was to compare the plasma profiles of LH and progesterone and the follicular dynamics in response to the administration of gonadorelin, lecirelin, or buserelin at the dose recommended to induce ovulation. In addition, the biological response to a half dose of lecirelin was assessed. Twelve healthy Holstein female cows were d…
-
72.
The objective of this study was to evaluate the effect of administering 200 µg versus 100 µg of GnRH as gonadorelin hydrochloride (Factrel; Zoetis, Parsippany, NJ) at the first GnRH injection (G1) of the breeding Ovsynch in a Double-Ovsynch (DO) protocol on pregnancy per artificial insemination (P/AI) at first service in lactating dairy cows. The study was conducted across 4 commercial dairies located in California (n = 2) and Wisconsin (n = 2). We also assessed the effect of GnRH dose on ovulat…
-
73.
To date, there have been no studies testing the capacity of GnRH analogs and respective doses to induce a LH peak in sheep. In this sense, the present study aimed to evaluate the capacity of different synthetic forms and doses of GnRH in inducing LH release in sheep, and the effect of GnRH administration at timed artificial insemination (TAI) on pregnancy per timed-AI. In experiment 1, ewes (n = 40) received an intravaginal device (IVD) of medroxyprogesterone acetate (MPA; 60 mg) for 7 d and pro…
-
74.
This study aimed to determine whether 200 μg of GnRH (gonadorelin hydrochloride) would increase ovulatory response and pregnancies per artificial insemination (P/AI) compared with 100 μg at the first GnRH of the breeding-Ovsynch of a Double-Ovsynch program (DO) in lactating Holstein cows. Weekly cohorts of primiparous (n = 719) and multiparous (n = 1,191) cows submitted to DO (GnRH, 7 d later PGF
-
75.
A highly specific antiserum against lamprey gonadotropin-releasing hormone (GnRH) was used to localize 1-GnRH in areas of the rat brain associated with reproductive function. Immunoreactive 1-GnRH-like neurons were observed in the ventromedial preoptic area (POA), the region of the diagonal band of Broca and the organum vasculosum lamina terminalis, with fiber projections to the rostral wall of the third ventricle and the organum vasculosum lamina terminalis. Another population of 1-GnRH-like ne…
-
76.
The effects of reserpine (catecholamine depletor) and LHRH analogues on gonadotropin secretion, spermiation and ovulation of common carp were investigated. Injections of reserpine alone at a dose of 1 or 7 mg/kg of body weight stimulated spermiation, and reserpine at a dose of 1 mg/kg of body weight in combination with (D-Arg6, Trp7, Leu8, Pro9, NEt)-LHRH (s-GnRH-A) or with (D-Ala6, Pro9)-LHRH (LHRH-A) at a dose of 50 micrograms/kg of body weight caused an increase of plasma gonadotropin levels,…
-
77.
The gold standard gonadotropin-releasing hormone (GnRH) stimulation test uses the response to intravenously injected gonadorelin to diagnose central precocious puberty (CPP). However, gonadorelin is not always readily available. This study investigated the diagnostic efficacy of the subcutaneous triptorelin test and the optimal blood sampling time for diagnosis of CPP. This study retrospectively examined the medical records of 220 girls who had undergone either the triptorelin or gonadorelin tes…
-
78.
Luteinizing hormone-releasing hormone (LHRH) agonists are believed to have higher cardiovascular risk relative to gonadotropin-releasing hormone (GnRH) antagonists. However, previous studies have not consistently demonstrated this. We used real-world clinical practice data to evaluate differences in major adverse cardiovascular events (MACE) risk between LHRH agonists compared to a GnRH antagonist following androgen deprivation therapy (ADT) initiation. We performed a retrospective analysis of d…
-
79.
Two experiments were conducted with bulls administered norgestomet and gonadorelin to determine if the gonadorelin-induced release of testosterone could be developed into a biological assay for quality assurance of gonadorelin. Implants containing norgestomet (0 to 36 mg) reduced the episodic release (r = -.81; P < .05) and mean concentrations of testosterone (r = -.82; P < .05). Gonadoreline-induced testosterone release increased (r = .99; P < .05) with increasing dosage of gonadorelin (up to 5…
-
80.
Our objective was to improve ovulatory response at the initiation of the Resynch-25 protocol by (1) increasing the dose of GnRH from 100 µg to 200 µg; and (2) giving a second GnRH treatment 56 h after the initiation of the protocol. We considered the experimental d 0 the day of the previous service. The experiment consisted of a 2 × 2 factorial design to compare the main effects of GnRH dose (100 vs. 200 µg) and GnRH treatment times (once vs. twice 56 h apart). A total of 2,111 previous services…
-
81.
An important problem of dairy industry worldwide is repeat breeder cows (RB). In this study, one farm in Northern Greece was chosen on the basis of subfertility. First, the available reproductive data of the previous year were evaluated; then, the farmer was advised to use the most common treatments for RB [GnRH with the third artificial insemination (AI+GnRH) or ovsynch in cows found empty after the second AI], and their efficacy was monitored throughout the year. Cows (n = 147) 2.5 to 4.5 year…
-
82.
Methods for the control of ovulation with GnRH or the GnRH analog D-Phe6 -LHRH (GnRH-A), were evaluated in gilts and sows as the last step in development of a fixed-time Al protocol. This involved 3 field trials using 2,744 gilts (10 units) and 71,628 sows (33 units). In Trial 1, the GnRH-A (75 microg) was given subsequent to treatment with altrenogest for cycle control or eCG for the stimulation of uniform follicle development in gilts. The release of LH was followed by ovulations which commenc…
-
83.
To clarify the impact of body mass index (BMI) on luteinizing hormone (LH) secretion in response to gonadorelin (GnRH) stimulation testing in girls diagnosed with idiopathic central precocious puberty (ICPP). Retrospective single-center cohort study was carried out in 865 confirmed ICPP girls who underwent GnRH stimulation tests. Pubertal development according to Tanner, sex hormone parameters, and LH secretion in response to GnRH-stimulation was compared. Around 609 girls were of normal weight…
- 84.
-
85.
Studies suggest that estrogen plays a contributing role in colorectal cancer. This project examined the preventive effects of raloxifene, a selective estrogen receptor modulator (SERM), and gonadorelin, an antiestrogenic drug, in female Apc(Min/+) mouse intestinal tumorigenesis. Six-week-old Apc(Min/+)mice were fed diet containing 1 ppm raloxifene or control diet. Gonadorelin (150 ng/mouse) was injected subcutaneously into one treatment group. Intestinal tumors were evaluated for tumor multiplic…
-
86.
We randomized 32 cycling female Sprague-Dawley rats (82 days old) into experimental and control groups (16 animals/group). Hyperinsulinemia was induced and maintained for 22 days in the experimental group with NPH human insulin (Novolin, Squibb-Novo, Princeton, NJ) as previously described. Controls received an identical volume of vehicle. Fifteen minutes before death, each rat received a sc injection of 100 ng synthetic GnRH (Factrel, Ayerst Laboratories, New York, NY). The mean serum insulin le…
-
87.
Does pituitary response to a GnRH stimulation test differ according to the different FSHB-211 G/T genotypes? The promoter polymorphism FSHB-211 G > T affects the pituitary response to exogenous GnRH stimulation by reducing FSH and increasing LH outputs. The FSHB-211 G > T single nucleotide polymorphism (SNP) is known to affect pituitary FSH output by impairing the transcriptional activity of FSHB. This was a cross-sectional, retrospective study on 67 male subjects (mean age: 24.6 ± 10.3 years) u…
- 88.
-
89.
Gonadotropin-releasing hormone (GnRH) is a major regulator and activator of the hypothalamic-pituitary-gonadal axis. Many studies have demonstrated the importance of GnRH in reproduction and sexual behaviour. However, to date, only a single study shows an involvement of GnRH in maternal behaviour where a 30% reduction of GnRH neurones abolishes a mother's motivation to retrieve pups. On this basis, we aimed to investigate the effects of acute central GnRH receptor blockade in lactating rats on m…
-
90.
The aim of this study was to evaluate the long-term effects of recombinant bovine somatotropin (rbST) on follicle population and ovulatory follicle development in non-lactating dairy cows. Twenty-one Jersey cows were allocated in rbST (n=11) or control (n=10) groups. On day -60, cows in rbST group received 500 mg of somatotropin (s.c. Lactotropin®, Elanco). On day 0, control and rbST cows received an intravaginal progesterone-releasing device (1.9 g, CIDR
-
91.
Lamprey gonadotropin-releasing hormone-III (l-GnRH-III), the putative follicle-stimulating hormone (FSH)-releasing factor (FSHRF), exerts a preferential FSH-releasing activity in rats both in vitro and in vivo. To test the hypothesis that l-GnRH-III acts on its own receptors to stimulate gonadotropin release, the functional activity of this peptide at mammalian (m) leutinizing hormone (LH)RH receptors transfected to COS cells was tested. l-GnRH-III activated m-LHRH receptors only at a minimal ef…
-
92.
Studies which have contributed to the present knowledge about peripheral effects of LHRH agonists are reviewed and compared with studies on the mechanism of effects of LHRH on the pituitary gland. It is concluded that LHRH or LHRH agonists can directly stimulate or inhibit the activity of gonadal cells from rats but not from man. Effects of LHRH on other human or rat peripheral tissues have been observed. LHRH- or LHRH-like molecules can be isolated from rat testes, but there is not enough evide…
- 93.
-
94.
Prostate cancer (PCa) routinely employs magnetic resonance (MR) imaging, while metastatic PCa needs more complicated detection methods for precise localization. The inconvenience of using different methods to detect PCa and its metastases in patients and the limitations of single-mode imaging have brought great challenges to clinicians. Meanwhile, clinical treatments for metastatic PCa are still limited. Herein, we report a targeted theranostic platform of Au/Mn nanodots-luteinising hormone rele…
-
95.
An immortalized hypothalamic neuronal cell line was recently developed by genetically targeting the expression of the simian virus-40 large T-antigen in LHRH neurons. These GT1 cells were subcloned to GT1-1, GT1-3, and GT1-7 cells, and they have been shown to express the mRNA for pro-LHRH and secrete LHRH-like immunoreactive (IR) materials into the media. The purpose of our study was to biochemically and immunologically characterize the IR materials within and secreted from these cells. Both LHR…
-
96.
There is increasing evidence that peptides of the gonadotropin-releasing hormone (GnRH) family, long considered a vertebrate preserve, are also present in invertebrate (molluscan) nervous systems. The possibility was examined that GnRHs are present and bioactive in cnidarians, considered to be representatives of the most primitive animals possessing a nervous system. Immunoreactive GnRH was detected in endodermal neurons of two anthozoans, the sea pansy Renilla koellikeri and the sea anemone Nem…
-
97.
The gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard for confirming the activation of the hypothalamic-pituitary-gonadal axis in central precocious puberty (CPP). However, it is time-consuming and costly. Our aim was to search for a simpler diagnostic modality for CPP by 1) evaluating the performance of basal serum luteinizing hormone (LH), 2) constructing a practical scoring system, and 3) determining the optimal single sampling time for serum LH in the GnRH stimulati…
-
98.
This study evaluated the influence of GnRH analogs (gonadorelin vs. buserelin) and doses (single vs. double) on LH release and ovulatory response in Bos indicus (Nelore) females on Day 7 of the estrous cycle. Cycling heifers and non-lactating cows were pre-synchronized: Day -10: progesterone (P4) implant insertion plus 2 mg of estradiol benzoate; Day -2: implant removal and 0.53 mg of cloprostenol sodium (PGF); Day 0: 25 μg of lecirelin (GnRH). Over four replicates, heifers (n = 57) and cows (n…
-
99.
Forty-six male teenagers 13-19 years old with delayed puberty (DP) underwent gonadotropin releasing hormone (GnRH) and human chorionic gonadotropin (HCG) stimulation as part of their work-up. All were followed to age 18 and beyond. Thirty-seven had constitutional delayed puberty (CDP). Nine had hypogonadotropic hypogonadism (HH). At referral 34 youngsters with CDP were properly diagnosed when the lower limit for the luteinizing hormone (LH) response to GnRH (Factrel 0.1 mg i.v.) was set at 12 IU…
-
100.
A synthetic derivative, GnRH [6-D-Phe], stable against enzymatic degradation, self-assembles and forms nanostructures and fibrils upon a pH shift in the presence of different concentrations of Zn
-
101.
The use of tail chalk and estrus/heat expression scores (HEATSC) evaluation is instrumental in identifying cows with greater estrus expression and greater artificial insemination pregnancy rates (P/AI) in cows submitted to timed artificial insemination (TAI), and cows with low or no estrus expression present lower P/AI. It was intended in this study to improve the pregnancy rates in TAI for Bos indicus beef cows, and gonadotrophin-releasing hormone (GnRH) injection was hypothesized to increase p…
-
102.
Gonadotropin-releasing hormone (GnRH) is considered a key player in reproduction. The caudal neurosecretory system (CNSS) is a unique neurosecretory structure of fish that may be involved in osmoregulation, nutrition, reproduction, and stress-related responses. However, a direct effect of GnRH on Dahlgren cells remains underexplored. Here, we examined the electrophysiological response of Dahlgren cell population of the CNSS to GnRH analog LHRH-A
-
103.
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) may play important roles in prostate cancer (PCa) progression. Specifically, LH expression in PCa tissues has been associated with metastatic disease with a poor prognosis, while FSH has been shown to stimulate prostate cell growth in hormone-refractory PCa cell lines. Gonadotropin-realizing hormone (GnRH) analogues are common agents used for achieving androgen deprivation in the treatment for PCa. GnRH analogues include LH-releasin…
-
104.
Kisspeptin (KP) is a major positive regulator of the hypothalamo-pituitary-gonadal axis and affects female reproductive cyclicity in mammals. It offers an attractive alternative strategy to control reproduction in fixed-time artificial insemination (FTAI) protocols. We aimed to evaluate the effects of different doses of kisspeptin-10 (KP-10) on sow reproductive performance in FTAI protocols. One hundred ninety-eight weaned sows were divided into three groups at random. A FTAI-GnRH group of sows…
-
105.
Gonadotropin-releasing hormone isoform I (GnRH), a neuro-deca-peptide, plays a fundamental role in development and maintenance of the reproductive system in vertebrates. The anomalous release of GnRH is observed in reproductive disorder such as hypogonadotropic hypogonadism, polycystic ovary syndrome (PCOS), or following prenatal exposure to elevated androgen levels. Quantitation of GnRH plasma levels could help to diagnose and better understand these pathologies. Here, a validated nano-high-per…
-
106.
This study looked at the effectiveness and financial benefits of treating repeat breeder (RB) dairy cows with the GnRH agonist gonadorelin 7-14 days after artificial insemination (AI). A total of 188 healthy dairy cows (2.4 ± 1.3 lactations) with an average milk yield of 42.1 ± 6.8 kg milk/day, at 179 ± 38.4 days in milk with 3.8 ± 1 AIs were divided into two groups, experimental (E group, n = 98) and control (C group, n = 90). The GnRH agonist gonadorelin was given 7-14 days after AI to the E g…
-
107.
Two experiments were conducted to compare pregnancy rates when GnRH or estradiol were given to synchronize ovarian follicular wave emergence and ovulation in an MGA-based estrus synchronization program. Crossbred beef cattle were fed melengestrol acetate (MGA, 0.5 mg per day) for 7 days (designated days 0-6, without regard to stage of the estrous cycle) and given cloprostenol (PGF; 500 microg intramuscular (im)) on day 7. In Experiment 1, lactating beef cows (n=140) and pubertal heifers (n=40) w…
-
108.
The aim of this review is to provide a comprehensive examination of the current literature describing the neural-immune interactions, with emphasis on the most recent findings of the effects of neurohormones on immune system. Particularly, the role of hypothalamic hormones such as Thyrotropin-releasing hormone (TRH), Corticotropin-releasing hormone (CRH) and Gonadotropin-releasing hormone (GnRH). In the past few years, interest has been raised in extrapituitary actions of these neurohormones due…
-
109.
Two experiments determined whether the addition of GnRH at the beginning of an estradiol (E2)/progesterone (P4)- based synchronization protocol and/or a second dose of prostaglandin F2α (PGF2α) the day before P4 device removal improves pregnancy rate in lactating dairy cows. On Day 0, all cows received a CIDR-B device and 2 mg i.m. estradiol benzoate, and half received 200 μg i.m. gonadorelin acetate (GnRH). On Day 7, cows were further subdivided to receive PGF2α (500 μg i.m. cloprostenol) or no…
-
110.
Our aim was to assess the GnRH-induced LH surge profile in dairy cows receiving two GnRH products (gonadorelin vs buserelin) given at proestrus or diestrus phase and to investigate whether season could alter LH surge profile in dairy cows. In Experiment 1, dairy cows at 108.2 ± 2.3 DIM, producing 41.5 ± 0.3 kg/day were randomized to receive, during proestrus and diestrus: Ovarelin
-
111.
Currently the standard treatment for bilateral cryptorchidism is bilateral surgical orchidopexy. Whether a hormonal treatment should be routinely administered postoperatively to increase fertility is debatable. Low-dose postoperative luteinizing hormone releasing hormone (LHRH) can increase spermatogonial numbers, but the effect of native LHRH (Kryptocur®) on adult fertility is unclear. To determine if low-dose every-second-day postoperative LHRH administration in children with bilateral cryptor…
-
112.
Several abstracts presented at the 2015 European Association of Urology Meeting highlighted new developments in hormone therapy for prostate cancer management. One abstract described how the luteinizing hormone-releasing hormone (LHRH)/gonadotropin-releasing hormone (GnRH) agonist leuprolide, but not the LHRH/GnRH antagonist degarelix, induced plaque instability in a mouse model. A second abstract showed that in patients with a history of severe cardiovascular disease, degarelix was associated w…
- 113.
-
114.
Human reproduction is controlled by the hypothalamic-pituitary-gonadal axis laid down early in fetal development. Luteinizing hormone releasing hormone (LHRH), also termed gonadotropin releasing hormone (GnRH), is a decapeptide and is a key molecule in this control circuit. It is produced by hypothalamic neurones, secreted in a pulsatile manner into the capillary plexus of the median eminence and effects the release of luteinizing hormone and follicle stimulating hormone from gonadotropic cells…
- 115.
-
116.
N6-methyladenosine is considered to be the most common and abundant internal chemical modification among the more than 150 identified chemical RNA modifications. It is involved in most biological processes and actively participates in the regulation of animal reproduction. However, the potential function of m
-
117.
An immortalized LHRH cell line has recently been developed by genetically targeting these neurons for tumorigenesis. One of the subclones, the GT1-7 cells, was characterized at both the light and electron microscopic levels to study the cellular and subcellular organization of these cells, particularly as they relate to biosynthesis, processing, and secretion. The cells were fixed onto slides 18-36 h after plating. LHRH and GnRH-associated peptide (GAP) immunoreactivities (IR) were detected by i…
-
118.
To validate further the existence of a specific hypothalamic follicle stimulating hormone releasing factor (FSHRF), stalk-median eminence (SME) fragments from sheep and whole hypothalami from male rats were purified by gel filtration on Sephadex G-25, and the gonadotropin-releasing activity on hemipituitaries of rats incubated in vitro was determined by bioassay and compared with the radioimmunoassayable luteinizing hormone releasing hormone (LHRH) and lamprey gonadotropin releasing hormone (l-G…
-
119.
The gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard for diagnosing central precocious puberty (CPP). Gonadorelin (Relefact) is used for the test but is not always readily available; triptorelin is used as an alternative. The purpose of this study was to evaluate the diagnostic validity of the triptorelin test compared with the GnRH test in the diagnosis of CPP in girls. This retrospective study included 100 girls with premature thelarche (PT) who underwent a hypothala…
-
120.
The present study aimed to evaluate the efficacy of different inducers of new follicular wave emergence (FWE) and ovulation in fixed-time artificial insemination (FTAI) synchronization protocols using norgestomet ear implants (NORG) in Bos indicus cattle. In Experiment 1, the synchronization of FWE was evaluated when two different estradiol esters in different doses [2mg estradiol benzoate (EB), 2.5mg EV or 5mg estradiol valerate (EV)] were administered with NORG implant insertion in B. indicus…
-
121.
The objective of the present study was to evaluate the efficacy of various methods for synchronization of follicular wave emergence (FWE) in pregnant heifers. Pregnant (60 d of gestation) Holstein heifers (n = 86) arranged in cohorts were randomly assigned to be administered 172 µg of gonadorelin acetate (GnRH), 3,300 IU of human chorionic gonadotropin (hCG), follicular ablation of follicles >5 mm (FA), or saline (control). Ultrasonography was performed to determine ovulation and emergence of a…
-
122.
Mammalian reproductive function is regulated by hypothalamic neurons that secrete Kisspeptin (Kp), a neuropeptide that stimulates gonadotropin-releasing hormone (GnRH) secretion, triggering pituitary gonadotrophins (LH and FSH) and gonadal steroids. This study evaluated the effect of Kisspeptin-10 (Kp10) on ovulation induction in rabbits, comparing its efficacy with that of the GnRH analogue gonadorelin. Multiparous New Zealand White × California does were assigned to three groups: control group…
-
123.
Sperm-zona pellucida binding, a crucial step in the process of fertilization, takes place in vivo in the upper portion of the fallopian tube. The presence of GnRH-like peptides in the female and the male genital tract has been described. In this work, the effect of GnRH and related peptides upon sperm-zona pellucida binding ability was studied. Sperm aliquots, capacitated for 4.5 h, were incubated for 5 min with saline (control) or 20 nM of GnRH, C-terminal (1-5) or N-terminal (5-10) fragments o…
-
124.
To explore the modulatory effects of gonadorelin on GABA-induced depolarization and GABA-activated current in membrane of rat primary sensory neurons. Intracellular recordings and whole-cell patch clamp techniques were performed on neurons in rat spinal ganglia (SG) preparation and neurons freshly isolated from rat SG, respectively. Drugs were applied by superfusion and/or by bath application. In the majority of neurons GABA (10 mumol.L-1 -1 mmol.L-1) induced a depolarization, which was blocked…
-
125.
Corticotrophin-releasing factor (CRF) is reported to inhibit the release of gonadotropin-releasing hormone (GnRH). In addition to the endocrine effects, GnRH is reported to influence the behavior via its neuronal interactions. We therefore, hypothesized that anxiety and depression produced by CRF could be also subsequent to the decrease in GnRH. To support such possibility, we investigated the influence of GnRH agonists on CRF or CRF antagonist induced changes in social interaction time in socia…
-
126.
Administration of GnRH analogues (agonists as well as antagonists) produces suppression of the pituitary---gonadal axis, thus inhibiting the secretion of LH, FSH and sexual steroids. For this reason, analogs are indicated in all those clinical situations where suppression of gonadotrophins (precocious puberty, contraception) or of sexual steroids (endometriosis, prostate hyperplasia, cancer, uterine fibroids) is desired. For several years GnRH agonists have been used in combination with gonadotr…
-
127.
The aim of this study was to compare the effect of the intramuscular administration of 50 μg of gonadorelin acetate versus natural mating, intrauterine infusion (i.u.) of a physiological relevant dose of either raw llama seminal plasma (SP) or purified beta-nerve growth factor from seminal origin (spβ-NGF) on ovulation rate and corpus luteum (CL) development and function in llamas. Females with a follicle (≥8 mm) were assigned to groups: (i) i.m. administration of 50 μg of gonadorelin acetate (G…
-
128.
In tambaqui (Colossoma macropomum), a rheophilic Amazonian fish of significant aquaculture importance that typically fails to spawn under captive conditions, gonadorelin has demonstrated potential in inducing ovulation and enabling strip spawning. However, the molecular mechanisms underlying gonadorelin action, particularly on the transcriptional regulation of follicle-stimulating hormone (fshβ) and luteinizing hormone (lhβ), remain poorly understood and warrant further investigation. The presen…
-
129.
<h4>Graphical abstract</h4><h4>Abstract</h4>Central precocious puberty (CPP) results from premature activation of the hypothalamic-pituitary-gonadal axis. The GnRH stimulation test remains the diagnostic gold standard, especially in girls with undetectable basal LH levels. However, native GnRH is expensive and often unavailable. Rapid-acting subcutaneous triptorelin has been proposed as a reliable alternative. This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin…
- 130.
-
131.
The objective was to evaluate the fertility of Bos indicus cows submitted to an ovulation synchronization protocol without estrogen (E2). In experiment 1, injectable P4 (P4i) was administered 10 days (D-10) before the TAI protocol. On D0, cows received one intravaginal P4 device and estradiol benzoate (EB; Control) or buserelin acetate (GnRH/EC and 2GnRH). On D8, devices were removed, and all cows received eCG and PGF2α. Additionally, cows received estradiol cypionate (EC) on D8 (Control and GnR…
-
132.
Queens are induced ovulators, and ovulatory success varies with hormonal status and stress. This study aimed to investigate the stress and hormone related factors influencing ovulatory success in 78 queens induced to ovulate by vaginal stimulation (VS), GnRH (50 μg gonadorelin), and human chorionic gonadotropin (hCG, 250 IU) in domestic cats. Before ovulation induction, stress scores, serum anti-Müllerian hormone (AMH) concentrations, age, body weight, and estrus day were recorded. Serum luteini…
-
133.
The aim of this study was to compare pregnancy per AI (P/AI) in resynchronization (Resynch) protocols using different hormonal combinations (estradiol benzoate [EB], a double dose of GnRH, or EB with a double dose of GnRH) administered on the day of progesterone (P4) device insertion. We hypothesized that combined administration of EB and GnRH on Day 25 after the first timed AI (TAI) is more efficacious than the administration of EB or GnRH alone in the resynchronization of estrus and ovulation…
- 134.
- 135.
-
136.
Hypogonadotropic hypogonadism (HH) is characterized by absent or insufficient secretion of GnRH and/or pituitary gonadotropins, which consequently leads to testicular dysfunction. HH is commonly associated with obesity, particularly in specific genetic syndromes, and its etiology appears heterogeneous and remains far from fully understood. This report describes the case of a 31-year-old male with HH and central obesity, who has a karyotype of 46, XY, t(1; 10)(q42; q24). He demonstrated a good pi…
-
137.
Fixed-time artificial insemination (FTAI) is currently a standardized protocol for pig reproductive management. Efficient ovulation synchronization induced by GnRH analogs is critical for ensuring the pregnancy outcomes of FTAI. However, among the widely used GnRH analogs, the degree of synchronization and timing of ovulation remain unclear in gilts. In the present study, we focused on the estrus-to-ovulation interval, a key component in fertility management programs, and directly compared the f…
-
138.
The administration of GnRH and its agonists benefits various aspects of bovine reproductive programs, encompassing physiological stages such as estrous synchronization, post-insemination, pregnancy, and the postpartum period. The positive impact of GnRH administration in overcoming challenges like repeat breeder cows, early embryonic loss prevention, and the management of cystic ovarian disease (COD) is thoroughly surveyed. Furthermore, this review focuses on the significance of GnRH administrat…
-
139.
Breast cancer is one of the most common malignant tumors among women, with approximately 50-60 % of cases overexpressing the luteinizing hormone-releasing hormone receptor (LHRH-R), making it an important therapeutic target. To overcome the limitations of conventional chemotherapy, this study designed and synthesized a novel LHRH-R-targeting peptide, LHRH-III', based on the structure of natural LHRH-III with rational structural modifications. Fluorescence labeling experiments demonstrated that t…
-
140.
This study evaluates the effectiveness and financial impact of treating anoestrus dairy cows using a modified DO protocol. Among the 350 cows included in the study, 142 (40.6%) were identified as anoestrus. The average daily milk production, days in milk at artificial insemination (AI), number of AIs, and parity were 33.8 ± 6.8 kg, 152.6 ± 24.4 days, 1.3 ± 0.2 AIs, and 1.9 ± 0.8 lactations, respectively. To assess embryo survival in anoestrus dairy cows undergoing the modified DO protocol, two g…
-
141.
<h4>Summary</h4>We describe two rare cases of primary bilateral macronodular adrenal hyperplasia (PBMAH) with mild autonomous cortisol secretion (MACS), incidentally discovered and further evaluated for aberrant cortisol responses to various stimuli. In both patients, morning serum cortisol levels remained elevated following 1 mg dexamethasone suppression test (DST) and 4 mg intravenous DST, while basal adrenocorticotropic hormone (ACTH) levels were suppressed. However, 24 h urinary free cortiso…
-
142.
<h4>Background</h4>Hypothalamic gonadotropin-releasing hormone (GnRH) plays a central role in regulating the pituitary-gonadal axis. The pulsatility of GnRH release is critical for maintaining the function of GnRH receptors and the secretion pattern of gonadotropins, namely follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which regulate endocrine function and follicular growth and maturation. During the luteal phase, LH is crucial for supporting a functional corpus luteum and sti…
- 143.
-
144.
<h4>Purpose</h4>The gonadotropin-releasing hormone (GnRH) stimulation test is regarded as the diagnostic gold standard for central precocious puberty (CPP); however, its invasiveness and limited accessibility restrict its routine use in clinical practice. Moreover, reported cutoff values for basal luteinizing hormone (LH) vary across studies, and simple screening models applicable to everyday clinical settings remain limited. This study aimed to evaluate routinely available clinical, biochemical…
-
145.
Gonadotropin-Releasing Hormone (GnRH) is a crucial neuropeptide that regulates reproductive functions in vertebrates. The study identifies and characterizes (GnRH) in the brain of <i>Tenualosa ilisha</i>, an iconic and lucrative Clupeiform fish from River Ganga, India. The current study aimed to analyze the GnRH gene in <i>T. ilisha</i> using an in silico study. The GnRH gene of <i>T. ilisha</i> comprises a full-length nucleotide sequence of 605 base pairs with an open reading frame of 312 base…
-
146.
At calving, 2,213 Holstein cows from 5 farms were enrolled in a study to establish potential associations between postcalving health disorders and reproductive performance and to determine the effectiveness in achieving pregnancy at first artificial insemination (AI) and the consequences on the proportion of cows pregnant by 150 DIM when using 2 different reproductive management programs for first service. Within farm, cows were randomly allocated to 2 reproductive schemes: (1) inseminating base…
-
147.
GnRH1 binds to its receptor GnRH1R to stimulate release of FSH and LH. Earlier NMR analysis had reported several possible conformers of GnRH1; however, the biologically active conformation of GnRH1 is not identified so far. Here, molecular docking of different NMR conformers of GnRH1 to GnRH1R is performed. Based on: (a) residues of GnRH1R interacting with antagonist elagolix (as ligand-binding pocket), (b) intermolecular hydrogen bonds (for specificity of interaction), and (c) total intermolecu…
-
148.
Previous studies have shown that the metabolite of gonadotropin-releasing hormone (GnRH), GnRH-(1-5), promotes migration and invasion in endometrial cancer cell lines through a non-canonical mechanism from its parental peptide. These studies showed that GnRH-(1-5) transactivates the epidermal growth factor receptor/extracellular signal-regulated kinases (EGFR/ERK) signaling pathway through an orphan G-protein-coupled receptor, GPR101, to stimulate matrix metalloproteinase-9 (MMP-9)-mediated EGF…
-
149.
An experiment was designed to evaluate modifications to the 7 & 7 Synch protocol, with the hypothesis that tandem administration of prostaglandin F2α (PG) and gonadotropin-releasing hormone (GnRH) during the presynchronization portion of the protocol would generate a convergent ovarian response among anestrous and estrous cycling females. Nulliparous, primiparous, and multiparous Angus and Angus-cross females were blocked based on parity and pre-treatment luteal status and, within a block, rando…
- 150.
-
151.
<h4>Problem</h4>Gonadotropin-releasing hormone (GnRH), primarily known for its hypothalamic role in regulating gonadotropin secretion, is also expressed in extra-hypothalamic tissues, including trophoblasts at implantation sites. We investigated the association between trophoblasts and mast cells, demonstrating their role in producing leukemia inhibitory factor (LIF) and matrix metalloproteinase-9 (MMP-9). Therefore, we hypothesized an additional interaction between trophoblasts and mast cells m…
- 152.
-
153.
<h4>Introduction</h4>Breast cancer is the main cause of cancer-related mortality in women in the developed world. In particular, receptors of luteinizing hormone-releasing hormone (LHRH or GnRH) are overexpressed in this malignant disease. The aim of this study was to develop a new molecular probe [99mTc]Tc-HYNIC-GSG-LHRH(<sc>d</sc>-Lys6)/tricine/nicotinic acid (NA) as a novel molecular imaging agent for breast cancer.<h4>Methods</h4>HYNIC-GSG-LHRH(D-Lys6) was acquired and radiolabeled with [99m…
-
154.
Central precocious puberty (CPP) diagnosis often requires invasive GnRH stimulation tests. Our purpose was to determine whether the IGF-1 and IGF-1 SDSs are reliable predictors of progressive CPP. This was a prospective study including 82 girls under 8 years of age. The participants were divided into CPP (n = 39), NP-CPP and IT (n = 26), and control groups (n = 17). Anthropometric measurements, Tanner staging, bone age, pelvic ultrasound, and serum IGF1 and IGF1-SDS level measurements were perfo…
-
155.
<b>Objectives</b>: Our aim is to report an uncommon pituitary activation occurring during the desensitization phase of the gonadotropin-releasing hormone agonist (GnRHa) long protocol, a cornerstone of medically assisted reproduction (MAR) therapy, in a young woman. <b>Results</b>: We present a case of a 33-year-old female patient with secondary infertility, who exhibited a prolonged and asynchronous follicular development during ovarian stimulation using the GnRH antagonist protocol. Therefore,…
-
156.
The current known data on the involvement of the peptidergic systems in breast cancer progression is overwhelmingly vast. Peptidergic systems are useful tools for imaging, diagnosis, prognosis and treatment of breast cancer. These systems play a crucial role in both basic and clinical breast cancer research by enabling the exploration of novel molecular mechanisms, signaling pathways, and the development of effective drug design strategies. Breast cancer cells overexpress peptide receptors; at t…
-
157.
<h4>Purpose</h4>Endometrial receptivity is a critical determinant of successful embryo implantation and pregnancy. Gonadotropin-releasing hormone (GnRH) analogues are widely used in in vitro fertilization (IVF) but their effects on endometrial receptivity remain incompletely understood. This study aims to investigate the impact of GnRH analogues on endometrial receptivity through various in vitro models.<h4>Methods</h4>Endometrial samples were collected across various stages of the menstrual cyc…
-
158.
<h4>Background</h4>The East African Shorthorn Zebu (SHZ) is a Bos indicus breed adapted to tropical farming systems characterized by compromised feeding, welfare and harsh environments, contributing to poor reproductive performance. Estrus and ovulation synchronization protocols developed to enhance reproduction in Bos taurus have not achieved similar success in SHZ. This study evaluated effects of 7-day Co-synch + progesterone releasing intravaginal device (7-day Co-synch + P4ID; n = 17), Bee-S…
- 159.
-
160.
<h4>Background</h4>Central precocious puberty (CPP) is diagnosed through a combination of clinical, auxological, and biochemical parameters, with pharmacological stimulation tests considered the diagnostic gold standard. In recent years, triptorelin, a long-acting Gonadotropin-Releasing Hormone (GnRH) analog, has been increasingly adopted in clinical practice due to limited availability of native GnRH.<h4>Objective</h4>To compare the clinical, auxological, and hormonal profiles of girls diagnose…
-
161.
The main objectives of the present study were to determine the effects of presynchronizing with a 1.0 g intravaginal progesterone device (IVPD) and prostaglandin F2α and to assess the effects of re-utilization of IVPD in a 2x2 factorial design, on the ovulatory response to first GnRH, ovarian status at different protocol stages, estrus expression and fertility in beef heifers submitted to a 5d-CO-Synch + Progesterone (P4) protocol. Beef heifers (n = 564) were assigned to 1 of 2 treatments at D-1…
-
162.
Hypothalamic gonadotropin-releasing hormone (GnRH) regulates the production of gonadotropins, which control reproduction. In elasmobranchs, unlike other gnathostomes, GnRH is released into the systemic circulation to stimulate gonadotrope cells located in the ventral lobe of the pituitary. The aim of this study was to investigate the potential role of systemic GnRH in the regulation of the testis in Scyliorhinus canicula. Phylogeny and synteny analyses identified three GnRHs and four GnRH recept…
-
163.
A 15-year-old female individual presented with primary amenorrhea and absence of pubertal signs. Her hormonal profile revealed isolated hypogonadotropic hypogonadism (IHH) with low levels of luteinizing hormone (LH), estradiol, and follicle-stimulating hormone (FSH), with a confirmatory luteinizing hormone-releasing hormone (LHRH) stimulation test. She has a background of global developmental delay and bilateral hearing loss, with computed tomography (CT) findings of an absent right incus lentic…
-
164.
The scallop (Chlamys farreri) is an important aquaculture species, and understanding its reproductive regulation is a major research focus. Previous studies have suggested that the orphan nuclear receptor fushi tarazu factor 1 (FTZF1), a member of the nuclear receptor subfamily 5 group A (NR5A), may play a role in regulating gonadal development and differentiation in scallops. In this study, we demonstrate through yeast one-hybrid assays that FTZ-F1 directly binds to the promoters of the gonadot…
-
165.
<h4>Purpose</h4>We aimed to compare the final adult height (FAH) of male patients with central precocious puberty (CPP) after treatment with a gonadotropin-releasing hormone agonist (GnRHa). Specifically, we compared FAH with the target height (TH) and the predicted adult height (PAH) before and after GnRHa treatment to quantify height gain and identify predictive factors.<h4>Methods</h4>We retrospectively reviewed the medical records of 92 male patients with CPP and known FAH after GnRHa treatm…
-
166.
Precise coordination between ovulation and insemination is essential for optimizing fixed-time artificial insemination (FTAI) in sows. This study compared ovulation timing and reproductive outcomes after treatment with recombinant human chorionic gonadotropin (rhCG), gonadorelin, or buserelin under estrus-triggered and fixed-time treatment protocols. A total of 285 sows received equine chorionic gonadotropin 24 h after weaning. In Trial 1, the ovulation-inducing treatments were administered at e…
Preprints (not yet peer-reviewed)
2-
167.
<title>Abstract</title> <p>Background Diagnosis of central precocious puberty (CPP) relies on biochemical confirmation of premature activation of the hypothalamic–pituitary–gonadal axis, with the GnRH stimulation test considered the reference standard. However, the test is time-consuming and burdensome, and current sampling schedules were established via older assay technologies. Objectives To evaluate whether optimizing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) sampling du…
-
168.
<title>Abstract</title> <p>The study evaluated the effect of two hormonal protocols on the ovarian activity and pregnancy rate of water buffaloes (<italic>Bubalus bubalis</italic>) outside the breeding season. Twenty multiparous Murrah × Mediterranean buffaloes were included. The protocols used were the following: 1) GnRH (n = 10): 100 µg gonadorelin IM (Day 0), 500 µg cloprostenol IM (Day 7), 100 µg gonadorelin IM (Day 9) and fixed time artificial insemination (FTAI) 18 h after the second GnRH;…
Case Reports
3-
169.
Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection. Treatment with luteinizing hormone-releasing hormone was discontinued and the immune response was characterized. Skin testing by skin prick test was positive for luteinizing hormone-releasing hormone but negative for vehicle. Radioallergosorbent testing was performed with allergic (patie…
-
170.
Gonadotropin-releasing hormone analogues are generally regarded as safe drugs. Gonadorelin acetate has been widely used for the diagnosis of central precocious puberty, and life-threatening reactions to gonadorelin acetate are extremely rare. Herein, we described - to the best of our knowledge - the first pediatric case in which severe anaphylaxis was encountered after intravenous gonadorelin acetate administration. An 8-year-old girl who was diagnosed with central precocious puberty was receivi…
-
171.
Two cases of hypogonadotropic hypogonadism caused by pituitary stalk interruption syndrome treated by pulse infusion of gonadorelin via micropump were reported, and their clinical features and the treatment process of pulse infusion of gonadorelin via micropump summarized. Both of the 2 patients were presented primarily with hypogonadotropic hypogonadism. After the treatment with pulse infusion of gonadorelin via micropump, their syndrome of androgen deficiency improved and the gonadotropin leve…
Curated sources on file
9- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.